The company
Iambic Therapeutics, Inc.
IAM · Nasdaq
We hold no 150-day reading for IAM yet: it needs about 200 sessions of history.
Statistics
- Rotation
- not in the set
- Weeks in an uptrend
- —
- Insider buys, 12 months
- $11.5M
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 0
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0
| Who | Did | Shares | Traded |
|---|---|---|---|
| Evan Lockwood RachlinDirector | bought | 718,750at $16.00 | 16 Oct 2026filed 19 Oct 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders0
New · exited0 · 0
Reported value$0
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|
News
No headline names it lately.
Everyone who traded it
Same industry
No other stock in its industry this week.
Government contracts
No federal award is tied to it.
From its SEC filings
No ratio computed from its SEC filings yet.
Analyst forecasts
No analyst forecasts yet.